Genotype-phenotype associations in PPGLs in 59 patients with variants in SDHX genes.
PPGL
genotype
phenotype
Journal
Endocrine connections
ISSN: 2049-3614
Titre abrégé: Endocr Connect
Pays: England
ID NLM: 101598413
Informations de publication
Date de publication:
Aug 2020
Aug 2020
Historique:
received:
29
06
2020
accepted:
19
07
2020
pubmed:
21
7
2020
medline:
21
7
2020
entrez:
21
7
2020
Statut:
ppublish
Résumé
Phaeochromocytomas and paragangliomas (PPGLs) are tumours of the adrenal medulla and extra-adrenal sympathetic nervous system which often secrete catecholamines. Variants of the SDHX (SDHA, -AF2, -B, -C, -D) genes are a frequent cause of familial PPGLs. In this study from a single tertiary centre, we aimed to characterise the genotype-phenotype associations in patients diagnosed with germline variants in SDHX genes. We also assessed whether systematic screening of family members resulted in earlier detection of tumours. The study cohort comprised all individuals (n = 59) diagnosed with a rare variant in SDHX during a 13-year period. Patient- and pathology records were checked for clinical characteristics and histopathological findings. We found distinct differences in the clinical and histopathological characteristics between genetic variants in SDHB. We identified two SDHB variants with distinct phenotypical patterns. Family screening for SDHB variants resulted in earlier detection of tumours in two families. Patients with SDHA, SDHC and SDHD variants also had malignant phenotypes, underlining the necessity for a broad genetic screening of the proband. Our study corroborates previous findings of poor prognostic markers and found that the genetic variants and clinical phenotype are linked and, therefore, useful in the decision of clinical follow-up. Regular tumour screening of carriers of pathogenic variants may lead to an earlier diagnosis and expected better prognosis. The development of a combined algorithm with clinical, genetic, morphological, and biochemical factors may be the future for improved clinical risk stratification, forming a basis for larger multi-centre follow up studies.
Identifiants
pubmed: 32688340
doi: 10.1530/EC-20-0279
pii: EC-20-0279
pmc: PMC7487185
doi:
pii:
Types de publication
Journal Article
Langues
eng
Pagination
793-803Références
Eur J Clin Invest. 2015 Sep;45(9):986-97
pubmed: 26183460
Am J Surg Pathol. 2009 Apr;33(4):599-608
pubmed: 19145205
J Clin Endocrinol Metab. 2006 Mar;91(3):827-36
pubmed: 16317055
Hum Mol Genet. 2010 Aug 1;19(15):3011-20
pubmed: 20484225
Hered Cancer Clin Pract. 2016 Jun 08;14:13
pubmed: 27279923
J Med Genet. 2020 Feb;57(2):96-103
pubmed: 31492822
Clin Epidemiol. 2015 Nov 17;7:449-90
pubmed: 26604824
Asian Pac J Cancer Prev. 2014;15(4):1751-5
pubmed: 24641403
J Clin Endocrinol Metab. 2017 Sep 1;102(9):3296-3305
pubmed: 28605453
J Urol. 2012 Dec;188(6):2063-71
pubmed: 23083876
Histopathology. 2018 Jan;72(1):106-116
pubmed: 29239034
Nat Rev Endocrinol. 2017 Apr;13(4):233-247
pubmed: 27857127
JIMD Rep. 2017;33:69-77
pubmed: 27604842
Endocr Pathol. 2019 Mar;30(1):64-73
pubmed: 30421319
J Intern Med. 2016 Dec;280(6):559-573
pubmed: 27165774
J Clin Endocrinol Metab. 2007 Mar;92(3):779-86
pubmed: 17200167
F1000Res. 2017 Dec 21;6:2160
pubmed: 29333259
Am J Surg Pathol. 2002 May;26(5):551-66
pubmed: 11979086
J Hum Hypertens. 1988 Oct;2(3):187-9
pubmed: 3236322
Clin Endocrinol (Oxf). 2019 Apr;90(4):499-505
pubmed: 30589099
Eur J Endocrinol. 2016 May;174(5):G1-G10
pubmed: 27048283
Cancers (Basel). 2019 Feb 15;11(2):
pubmed: 30769931
Biochim Biophys Acta. 2011 Nov;1807(11):1432-43
pubmed: 21771581
Genet Med. 2015 May;17(5):405-24
pubmed: 25741868
J Med Genet. 2020 Apr;57(4):217-225
pubmed: 31649053
J Clin Endocrinol Metab. 2014 Jun;99(6):1915-42
pubmed: 24893135
Mod Pathol. 2003 Mar;16(3):246-55
pubmed: 12640105
Thyroid. 2017 Dec;27(12):1505-1510
pubmed: 29020875
Horm Metab Res. 2012 May;44(5):349-53
pubmed: 22566194